Urolon CEO Nicoline van Woerkum. Image: Urolon

Stress Urinary Incontinence (SUI) is the most common type of urinary incontinence. According to estimations around 1 in 3 women will experience bladder leakage at some point in their life. SUI happens when the sphincter muscle that controls the urethra, the pelvic floor tissues and muscles that are used to keep the urethra closed, weakens. Urolon developed by Netherlands-based AQLANE Medical, is solving for this.

Urolon is a bioresorbable, non-permanent filler that is completely removed from your body over time. The treatment is minimally invasive, takes around 20 minutes and can be performed in a hospital or clinic. Three small injections into the urethral wall restore its closure.

According to patient research shared by AQLANE Medical, the preferred treatment option for SUI after pelvic floor muscle therapy should ideally be minimally-invasive, safe, effective and not placing any permanent materials in the body. Urolon is just that and aims to close the gap between conservative and surgical intervention after pelvic floor muscle therapy offering patients a new alternative.

How It Works

Urolon’s principle components are synthetic polycaprolactone (PCL) microspheres suspended in a carboxymethylcelulose (CMC) gel carrier. PCL is a well-known totally bioresorbable soft medical polymer and has been used in numerous CE marked and US FDA approved bioresorbable product applications for several decades and has demonstrated an excellent safety profile.

According to clinical data Urolon combines this excellent safety profile with strong efficacy data and Quality of Life (QoL) improvements up to 2 years. The bioresorption profile, minimally-invasive approach and simple nature of the procedure make Urolon a potentially first-line treatment option for mild to moderate SUI.

Urolon’s UK Launch

After receiving CE certification in 2018 and successful introduction in the European Union, the company is now expanding the the UK. Urolon’s UK activities will be led by Patricia Haughney, who has extensive experience in Urology and Women’s Health. It is expected that Urolon will be available in the first treatment centers in the UK in Q4 2022.

Nicoline van Woerkum, CEO of Urolon, shares: “We are very excited to introduce Urolon in the UK. Since 2018 we have successfully treated many women and can conclude that there is a large untapped market that consists of women that are looking for a treatment for SUI, but they do not wish to have permanent materials placed in their bodies. Especially women in their peak reproductive years. By making Urolon available in the UK, we continue our mission to improve the quality of life of women suffering from SUI. We strive to make Urolon the gold standard after pelvic floor muscle therapy.”

Show CommentsClose Comments

Leave a comment